Marstacimab recommended for EU approval for hemophilia A and B
A European Medicines Agency (EMA) committee has issued a positive opinion recommending the approval of marstacimab in the European Union for preventing bleeding episodes in people with severe hemophilia A or hemophilia B without inhibitors. The European Commission will now review the recommendation, made by the…